C-J0SDKatairo GmbH
lipofuscin removal, retinal pigment epithelium, ophthalmology
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-J0SD
C-J0SDC-J0SDlipofuscin removal, retinal pigment epithelium, ophthalmology
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Katairo GmbH lipofuscin removal, retinal pigment epithelium, ophthalmology
Katairo GmbH is developing Remofuscin for seriously disabling eye indications. The company states that Remofuscin removes lipofuscin from living cells in the retinal pigment epithelium, an effect previously believed to be impossible. Remofuscin is being developed for Stargardt disease and dry age-related macular degeneration, with both indications entering Phase 2.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Katairo GmbH — Translational · Bottom quartile. Derived deterministically from 2 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 depth (2 programs at…
Source: Deterministic